Abstract

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies
... Madhu Anant
Blood | VOL. 138
, et. al. ... Madhu Anant
05 Nov 2021
A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
Farhad Ravandi ... Lade Adewale
Blood | VOL. 138
Farhad Ravandi, et. al.Farhad Ravandi ... Lade Adewale
05 Nov 2021
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Roland B Walter ... Pau Montesinos
Blood | VOL. 138
Roland B Walter, et. al.Roland B Walter ... Pau Montesinos
05 Nov 2021
Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative
Moshe Grunspan ... Joshua F Zeidner
Blood | VOL. 138
Moshe Grunspan, et. al.Moshe Grunspan ... Joshua F Zeidner
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study.
Linda Sundler Björkman ... Bengt Zöller
Blood | VOL. -
Linda Sundler Björkman, et. al.Linda Sundler Björkman ... Bengt Zöller
17 May 2024
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Jennifer A Woyach ... Veerendra Munugalavadla
Blood | VOL. -
Jennifer A Woyach, et. al.Jennifer A Woyach ... Veerendra Munugalavadla
16 May 2024
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Chiara Malinverni ... Carlo Visco
Blood | VOL. -
Chiara Malinverni, et. al.Chiara Malinverni ... Carlo Visco
16 May 2024
Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML.
Jacqueline A Cook ... Andrew J Menssen
Blood | VOL. -
Jacqueline A Cook, et. al.Jacqueline A Cook ... Andrew J Menssen
15 May 2024
View more papers